
CBO Estimate of the Statutory Pay-As-You-Go Effects for H.R. 1919, Safeguarding America's Pharmaceuticals Act of 2013, as Provided to CBO on May 31, 2013 (H1919_SUS)

June 3, 2013

	By Fiscal Year, in Millions of Dollars											2013 -	2013 -
	2013	2014	2015	2016	2017	2018	2019	2020	2021	2022	2023	2018	2023
NET DECREASE (-) IN THE DEFICIT													
Statutory Pay-As-You-Go Impact	0	0	-6	-6	-6	-1	-1	-1	-1	-1	-1	-19	-24

Source: Congressional Budget Office.

Note: The legislation would require the Food and Drug Administration (FDA) to establish national standards for monitoring the movement of prescription drugs through the drug distribution system. The “drug distribution system” encompasses the network of companies that produce, handle, distribute, and dispense drug products. The legislation also would require the FDA to establish a licensing program for certain third parties that provide logistic services to support pharmaceutical manufacturers, wholesalers, and dispensers. CBO estimates that enacting H.R. 1919 would increase federal revenues from the collection of licensing fees from third parties.